3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
152
Neoplasm Metastasis
22
Neoplasms
21
Ovarian Neoplasms
12
Sarcoma
10
Pancreatic Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Melanoma
7
Endometrial Neoplasms
7
Colorectal Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Prostatic Neoplasms
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Multiple Myeloma
6
Lymphoma, Non-Hodgkin
6
Head and Neck Neoplasms
6
Carcinoma, Renal Cell
6
Recurrence
5
Medulloblastoma
5
Lung Neoplasms
5
Leukemia, Myeloid, Acute
5
Breast Diseases
5
Triple Negative Breast Neoplasms
4
Sarcoma, Ewing
4
Neoplasms by Site
4
Lymphoma, Mantle-Cell
4
Liposarcoma
4
Glioma
4
Glioblastoma
4
Colonic Neoplasms
4
Interventions
Standard of Care
8
Hydroxychloroquine
4
BNT162 Vaccine
4
Practice Guidelines as Topic
3
Blood Specimen Collection
3
2019-nCoV Vaccine mRNA-1273
3
tocilizumab
2
sotrovimab
2
cilgavimab and tixagevimab drug combination
2
Specimen Handling
2
Sodium Chloride
2
CVnCoV COVID-19 vaccine
2
COVID-19 Vaccines
2
COH04S1 COVID-19 vaccine
2
Azithromycin
2
sinovac COVID-19 vaccine
1
selinexor
1
remdesivir
1
proxalutamide
1
palbociclib
1
ogalvibart
1
monalizumab
1
lenzilumab
1
crexavibart
1
ciclesonide
1
bemcentinib
1
avdoralimab
1
acalabrutinib
1
XAV-19
1
Therapeutics
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
COVID-19
×
palbociclib
×
Clear all
NCT05371275
2022-11-07
CDK6COV
biotx.ai GmbH
Phase 2
Withdrawn